|
π
|
Safety of anacetrapib in patients with or at high risk for coronary heart disease.
13 auth.
C. Cannon,
Sukrut Shah,
H. Dansky,
M. Davidson,
E. Brinton,
A. Gotto,
M. Stepanavage,
S. Liu,
Patrice Gibbons,
T. B. Ashraf,
...
Jennifer Zafarino,
Y. Mitchel,
P. Barter
|
9 |
2010 |
9
π
|
|
π
|
HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment
43 auth.
R. Haynes,
Lixin Jiang,
J. Hopewell,
Jing Li,
Fang Chen,
S. Parish,
M. Landray,
R. Collins,
J. Armitage,
R. Collins,
J. Armitage,
C. Baigent,
Z. Chen,
M. Landray,
Y. Chen,
...
L. Jiang,
T. Pedersen,
L. Bowman,
F. Chen,
M. Hill,
R. Haynes,
C. Knott,
K. Rahimi,
J. Tobert,
P. Sleight,
D. Simpson,
S. Parish,
A. Baxter,
M. Lay,
C. Bray,
E. Wincott,
G. Leijenhorst,
A. SkattebΓΈl,
G. Moen,
Y. Mitchel,
O. Kuznetsova,
S. MacMahon,
J. Kjekshus,
C. Hill,
T. Lam,
P. Sandercock,
R. Peto,
J. Hopewell
|
9 |
2013 |
9
π
|
|
π
|
2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials.
64 auth.
K. Hicks,
K. Mahaffey,
R. Mehran,
S. Nissen,
S. Wiviott,
B. Dunn,
S. Solomon,
J. Marler,
J. Teerlink,
A. Farb,
D. Morrow,
S. Targum,
C. Sila,
Mary Thanh Hai,
M. Jaff,
...
Hylton V. Joffe,
D. Cutlip,
Akshay S. Desai,
E. Lewis,
C. Gibson,
M. Landray,
A. Lincoff,
C. White,
Steven S. Brooks,
K. Rosenfield,
M. Domanski,
A. Lansky,
J. McMurray,
J. Tcheng,
S. Steinhubl,
P. Burton,
L. Mauri,
C. O'connor,
M. Pfeffer,
H. M. Hung,
N. Stockbridge,
B. Chaitman,
R. Temple,
Heather D. Fitter,
K. Illoh,
K. Cavanaugh,
B. Scirica,
I. Irony,
Rachel E. Brown Kichline,
Jonathan G. Levine,
Anna Park,
Leonard V Sacks,
A. Szarfman,
E. Unger,
Lori Ann Wachter,
Bram D. Zuckerman,
Y. Mitchel,
Douglas Peddicord,
T. Shook,
Bron Kisler,
C. Jaffe,
R. Bartley,
D. DeMets,
MariJo Mencini,
Cheri Janning,
Steve Bai,
J. Lawrence,
R. DβAgostino,
S. Pocock
|
8 |
2018 |
8
π
|
|
π
|
Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients.
9 auth.
D. Bloomfield,
G. Carlson,
A. Sapre,
D. Tribble,
J. Mckenney,
T. Littlejohn,
...
C. Sisk,
Y. Mitchel,
R. Pasternak
|
7 |
2009 |
7
π
|
|
π’
|
Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial.
A. Goldberg,
A. Sapre,
Ji Liu,
R. Capece,
Y. Mitchel
|
7 |
2004 |
7
π’
|
|
π
|
Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia.
11 auth.
J. Paolini,
Y. Mitchel,
Robert Reyes,
U. Kher,
E. Lai,
D. Watson,
...
J. Norquist,
A. Meehan,
H. Bays,
M. Davidson,
C. Ballantyne
|
7 |
2008 |
7
π
|
|
π
|
Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention.
14 auth.
E. Bohula,
D. Morrow,
R. Giugliano,
M. Blazing,
Ping He,
Jeong-Gun Park,
S. Murphy,
Jennifer A. White,
Y. Kesaniemi,
T. Pedersen,
...
A. Brady,
Y. Mitchel,
C. Cannon,
E. Braunwald
|
7 |
2017 |
7
π
|
|
π
|
Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S).
9 auth.
K. PyoΜraΜlaΜ,
C. Ballantyne,
B. Gumbiner,
Michael W Lee,
Arvind K. Shah,
M. Davies,
...
Y. Mitchel,
T. Pedersen,
J. Kjekshus
|
7 |
2004 |
7
π
|
|
π
|
The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day.
13 auth.
M. H. Davidson,
E. Stein,
C. Dujovne,
D. Hunninghake,
S. Weiss,
R. Knopp,
D. Illingworth,
Y. Mitchel,
M. Melino,
R. Zupkis,
...
M. Dobrinska,
R. Amin,
J. Tobert
|
7 |
1997 |
7
π
|
|
π
|
Effect of cholesterol-lowering therapy on coronary endothelial vasomotor function in patients with coronary artery disease.
12 auth.
J. Vita,
A. Yeung,
M. Winniford,
J. Hodgson,
C. Treasure,
J. Klein,
...
S. Werns,
M. Kern,
D. Plotkin,
W. Shih,
Y. Mitchel,
P. Ganz
|
7 |
2000 |
7
π
|
|
π
|
Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial.
9 auth.
D. Illingworth,
E. Stein,
Y. Mitchel,
C. Dujovne,
P. Frost,
R. Knopp,
...
P. Tun,
R. Zupkis,
R. Greguski
|
6 |
1994 |
6
π
|
